Using PK/PD Modeling for Antibody Drug Conjugate Translation
About this webinar
Antibody Drug Conjugates (ADCs) are at the forefront of the therapeutic market. The first therapeutic antibody was approved by the U.S. Food and Drug Administration (FDA) in 1986. Since then, the pharmaceutical industry has sought opportunities to leverage antibody technology as therapeutic agents to treat human disease. PK/PD modeling has been a useful technique to integrate data generated from diverse test platforms in mechanism framework.
This webinar will focus on :
- Introduction to Antibody Drug Conjugate (ADC)
- Development of mechanistic PK/PD model for preclinical-to-clinical translation of ADCs
- Application of PK/PD modeling to understand the disposition of ADCs and guide the development of ADC
A live Q&A with the audience will follow the presentation.
Who should attend
- Antibody-Drug Conjugates
- Pre-Clinical/Clinical Development
- Oncology
- PK
- Target Validation
- Protein/Antibody Engineering
- R&D
- Formulation
- CMC & Regulatory
- QA/QC
Featured Speakers
Dhaval Shah, PhD
Dr. Shah worked as a Prinicpal Scientist at Pfizer prior to his current position as Assistant Professor at UB, The State University of New York, his alma mater. Dr. Shah’s research interests include discovery and development of novel biological drugs like ADCs for the treatment of cancer, obesity. His work integrates the principles of PK/PD and mathematical modeling to quantify the efficacy and toxicity of drugs, which in turn provides a predictive systems framework for successful preclinical-to-clinical translation of drugs.
Partner for this event
eCademy
Related webinars
More from Myriad RBM.
Enabling Precision Medicine with Complex Companion Diagnostic Tools
Translating the Preclinical Pharmacology of the Select TLR8 Agonist VTX-2337, into Clinical Activity using the Myriad RBM MAP Inflammation Panel
Detecting the Undetectable: Development & Validation of Ultrasensitive Simoa-based Immunoassay Services